Bleeding

A glycoprotein VI inhibitor (Revacept, AdvanceCor) as alternative platelet inhibition strategy during PCI for CAD.

Low-dose edoxaban (Savaysa, Daiichi Sankyo) vs. placebo for prevention of stroke and systemic embolism in patients aged at least 80 years with AF.

Among patients on oral anticoagulation, those who had dual antiplatelet therapy for 14 days after PCI with a nanocoated stent had worse outcomes compared with those assigned 3-to-6-month DAPT after PCI with a drug-eluting stent.

Dual antiplatelet therapy for 1 month or 3 months was noninferior to a 12-month duration with regard to all-cause mortality and MI in patients with high bleeding risk undergoing PCI, researchers found.

Among patients with STEMI who underwent PCI with an ultrathin bioresorbable polymer sirolimus-eluting stent, switching to ticagrelor monotherapy after 3 months reduced bleeding risk, according to the TICO-STEMI trial.

Medtronic announced that the FDA approved an expanded indication for a drug-eluting stent to include patients with high bleeding risk who take dual antiplatelet therapy for 1 month after PCI.

The NIH has awarded a $1.7 million grant to fund research into potential treatments for hereditary hemorrhagic telangiectasia, a frequently misdiagnosed but potentially life-threatening bleeding disorder.

The landmark TAILOR-PCI trial showed encouraging evidence for genotype-guided antiplatelet therapy.

Among patients 80 years or older, treatment of ACS with ticagrelor was associated with greater risk for death and bleeding compared with clopidogrel, researchers reported.

A higher dose of a glycoprotein VI inhibitor in patients with CAD who underwent PCI resulted in more pronounced platelet inhibition without increasing bleeding risk, researchers found in the ISAR PLASTER trial.